Literature DB >> 21910779

Sustained high prevalence of pneumococcal serotype 1 in paediatric parapneumonic empyema in southern Spain from 2005 to 2009.

I Obando1, M S Camacho-Lovillo, A Porras, M A Gandía-González, A Molinos, I Vazquez-Barba, B Morillo-Gutierrez, O W Neth, D Tarrago.   

Abstract

The epidemiology and microbiological characteristics of paediatric parapneumonic empyema (PPE) before the introduction of the new generation of conjugate pneumococcal vaccines (10-valent and 13-valent) are described. All patients <14 years old admitted to a tertiary paediatric hospital with a diagnosis of PPE were prospectively enrolled from January 2005 to December 2009. Pneumococcal serotyping of culture-negative pleural fluid samples was performed using a multiplex real-time PCR assay. Overall, 219 patients had PPE. Incidence rates for PPE remained stable during the study period with a not significant increase in 2009 compared with 2005 (p 0.13), and were temporally associated with higher circulation of pandemic influenza A H1N1 during the last quarter in our population (p 0.001). Pneumococci were detected in 72% of culture-positive and 79% of culture-negative samples. Serotypes were determined in 104 PPE cases. Serotype 1 was the most prevalent serotype identified (42%) followed by serotypes 7F (20%), 3 (16%), 19A (8%) and 5 (7%). Serotype distribution remained similar during all time periods. Pneumococcal serotype 1 remained the most common cause of PPE during the 5-year study. The new generation of pneumococcal conjugate vaccines offers potential serotype coverage of 73% (10-valent) and 99% (13-valent) in the population studied suffering from PPE. Continuous epidemiological and molecular studies are paramount to monitor the impact of pneumococcal vaccines on the epidemiology of PPE.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910779     DOI: 10.1111/j.1469-0691.2011.03632.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Simultaneous identification of 29 prevalent invasive pneumococcal serotypes or pairs of serotypes by hybridization-ligation PCR.

Authors:  Montserrat Ortega Doménech; David Tarragó Asensio
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

Review 2.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

Review 3.  Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology.

Authors:  M A Fletcher; H-J Schmitt; M Syrochkina; G Sylvester
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-23       Impact factor: 3.267

4.  The relevance of pneumococcal serotypes.

Authors:  Chamira Rodrigo; Wei Shen Lim
Journal:  Curr Infect Dis Rep       Date:  2014-04       Impact factor: 3.725

Review 5.  Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.

Authors:  Lucia H Lee; Xin-Xing Gu; Moon H Nahm
Journal:  Vaccines (Basel)       Date:  2014-02-14

6.  Whole Exome Sequencing Identifies New Host Genomic Susceptibility Factors in Empyema Caused by Streptococcus pneumoniae in Children: A Pilot Study.

Authors:  Antonio Salas; Jacobo Pardo-Seco; Ruth Barral-Arca; Miriam Cebey-López; Alberto Gómez-Carballa; Irene Rivero-Calle; Sara Pischedda; María-José Currás-Tuala; Jorge Amigo; José Gómez-Rial; Federico Martinón-Torres
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

7.  Etiology of parapneumonic effusion and pleural empyema in children. The role of conventional and molecular microbiological tests.

Authors:  Katarzyna Krenke; Ewa Sadowy; Edyta Podsiadły; Waleria Hryniewicz; Urszula Demkow; Marek Kulus
Journal:  Respir Med       Date:  2016-05-10       Impact factor: 3.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.